Gene therapy may be a cure for post-radical prostatectomy erectile dysfunction

April 28, 2003

CHICAGO, April 28 - Researchers from the University of Pittsburgh Medical Center (UPMC) have found that gene therapy may not only be a feasible, but also may be an ideal treatment for neuropathic erectile dysfunction (ED).

Neuropathic ED results from damage to the nerves essential to achieving and maintaining an erection and is experienced by 79.6 percent of men who undergo radical prostatectomies. Results of the study were presented today at the annual meeting of the American Urological Association (AUA) and are published in abstract 1179 of the AUA proceedings.

"While radical prostatectomy can be a cure for early stage prostate cancer in a large percentage of patients, there are a number of risks and side effects that patients must consider when deciding on whether to have the surgery or not - one of those being the high likelihood of experiencing erectile dysfunction." said Michael Chancellor, M.D., director of neurourology at UPMC and professor of urology at the University of Pittsburgh School of Medicine. "If by using gene therapy prior to surgery, we can minimize nerve damage and preserve the patient's ability to have an erection, the patient may be less reluctant to have the potentially life-saving procedure."

In the study, researchers injected herpes simplex virus vectors that deliver neurotrophic factors, factors that facilitate the recovery of injured nerves, into the corpus cavernosum or cavernous nerve of rats at the time of cryo-injury to the cavernous nerve. The cavernous nerve is the nerve that stimulates erection; cryo-injury has similar effects on the nerve as radical prostatectomy. After injection, they found that the viral vectors transported the neurotrophic factors to the nerve. On electrical nerve stimulation, nerve-injured rats that expressed the viral vector experienced an increase in intracavernous pressure.

The researchers hope that this concept can be translated into humans, enabling gene therapy to be used as a prophylactic treatment for men undergoing radical prostatectomy.

Radical prostatectomy is used to treat the early stages of prostate cancer by surgically removing the prostate gland and surrounding tissue. The procedure has a success rate of 70 to 85 percent. A high percentage of patients experience ED after the procedure due to injury to the peripheral nerves, including the cavernous nerve, located close to the prostate gland.

In addition to studying the use of gene therapy to treat post-radical prostatectomy ED, the team from the University of Pittsburgh also is investigating the potential of using muscle derived stem cells to regenerate the peripheral nerves often damaged by radical prostatectomy.

This study is published in abstract 1256 of the AUA proceedings.

kr/04-16-03
-end-
CONTACT:
Jocelyn Uhl
Clare Collins
PHONE: 412-647-3555
FAX: 412-624-3184
E-MAIL:
UhlJH@upmc.edu
CollCX@upmc.edu


University of Pittsburgh Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.